Indian startups bag $1.11B across 19 deals; Honasa buys into nutraceuticals via Fluence Pharma
Week of June 22-27 saw $1.11B deployed across 19 deals, led by Meta's $900M into CRED. Honasa (Mamaearth) acquired 58% of Fluence Pharma at Rs 135 cr EV, entering nutraceuticals. Square Yards raised Rs 900 cr; Bodycraft and AllHome also tapped capital. Secondaries hit Pine Labs and Delhivery as Actis and Alpha Wave exited stakes.
What happened
Mamaearth (Honasa Consumer) · Weekly roundup: Indian startups raised $1.11B across 19 deals. Honasa acquired 58% of Fluence Pharma entering nutraceuticals;
Key facts
- $1.11 billion raised across 19 deals
- Meta $900M into CRED
- Square Yards Rs 900 cr (~$95M)
- AllHome Rs 200 cr (~$21M)
- Bodycraft Rs 120 cr (~$12.6M)
- Honasa 58% stake in Fluence Pharma at Rs 135 cr EV
- 91trucks 100 layoffs
- Actis sold ~2% Pine Labs for Rs 371 cr
- Alpha Wave exits Delhivery Rs 665 cr
Why this matters
Honasa's 58% stake in Fluence at Rs 135 cr EV sets a benchmark for strategic D2C-to-pharma roll-ups, while Actis and Alpha Wave exits flag rising secondary supply for incoming buyers.
What to watch
- Honasa filing disclosures on Fluence revenue and integration roadmap
- FSSAI or CDSCO regulatory shifts on nutraceutical claims and D2C distribution
- Next BPC-adjacent acquisition by a listed D2C player within 60 days
- CRED's deployment of Meta capital—payments, lending, or commerce vertical
- Weekly deal count dropping below 15 or ex-mega-deal volume under $200M
- Track Fluence Pharma SKU launches on Mamaearth/Derma Co sites within 90 days
- Monitor Honasa Q2 commentary on nutraceuticals revenue contribution and margin profile
- Scan for copycat BPC-pharma M&A announcements at sub-Rs 200cr ticket sizes
- Watch Square Yards deployment of Rs 900cr—proptech expansion or distressed inventory play
- Map secondary buyers at Pine Labs/Delhivery to gauge late-stage appetite vs. exit fatigue